Skin cancer is the most common of all cancer PROCEEDINGS CLINICAL UPDATE ON ACTINIC KERATOSIS* Murad Alam, MD ABSTRACT
|
|
- Britney Fleming
- 5 years ago
- Views:
Transcription
1 CLINICAL UPDATE ON ACTINIC KERATOSIS* Murad Alam, MD ABSTRACT Cutaneous squamous cell carcinoma (SCC) accounts for approximately cancer cases each year in the United States, but is associated with a low mortality rate if detected and treated early. Actinic keratosis (AK) is an important precursor lesion for invasive SCC. The likelihood of AK is increased by a number of risk factors, but especially by long-term exposure to sunlight. AKs typically present as scaly or flaky lesions that are often easier to feel than see. AKs are usually diagnosed clinically a skin biopsy is often obtained for lesions that have failed to respond to repeated treatment attempts, or to rule out SCC. Patients should be encouraged to use preventive measures, such as sunscreen or sunprotective clothing, to reduce the risk of AK. It is not possible to determine which AKs are likely to progress to invasive skin cancer, or when such progression is likely to occur, thus it is important to treat all AKs. Treatment options may be classified as either lesion directed or field directed. Lesion-directed therapies (eg, cryosurgery using liquid nitrogen) are generally used to remove *Based on proceedings from a satellite symposium at the Annual Meeting of the American Academy of Family Physicians on October 6, 2007, in Chicago, Illinois. Associate Professor of Dermatology, Otolaryngology, and Surgery, Chief, Cutaneous and Aesthetic Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Address correspondence to: Murad Alam, MD, Associate Professor of Dermatology, Otolaryngology, and Surgery, Chief, Cutaneous and Aesthetic Surgery, Northwestern University Feinberg School of Medicine, 676 N St Clair Street, Suite 1600, Chicago, IL m-alam@northwestern.edu. small numbers of lesions. Field-directed therapies, which affect a relatively large area of skin surface, are used to treat a large number of AKs and also to prevent the appearance of new AKs within a sun-damaged skin region. Several fielddirected therapies are available, including 5- fluorouracil, imiquimod, and topical diclofenac. Photodynamic therapy or destructive therapies (eg, dermabrasion and chemical peels) may also be options for some patients. All of these options are associated with high cure rates and a low probability of progression to invasive skin cancer. (Adv Stud Med. 2008;8(2):30-35) Skin cancer is the most common of all cancer types diagnosed in the United States. More than 1 million cases of skin cancer are diagnosed each year in the United States, accounting for nearly 50% of all cancer cases. 1 In general, skin cancers may be classified as either melanoma or nonmelanoma skin cancer (NMSC). NMSC alone accounts for approximately 33% of cancer cases in the United States, and includes basal cell carcinoma and cutaneous squamous cell carcinoma (SCC). 2 Cutaneous SCC is distinct from oral SCC or SCC of the head and neck, which are usually treated by radical resection and are generally associated with poor treatment outcomes. In contrast, cutaneous SCC is a very treatable condition with a favorable prognosis if detected early. There are approximately cases of cutaneous SCC per year in the United States, and there are approximately 2000 to 2500 annual deaths attributable to cutaneous SCC. 2 Further, it should be noted that the prevalence of cutaneous SCC has increased substantially since the 1960s, which may reflect changing lifestyles and increased voluntary sun exposure. 3,4 30 Vol. 8, No. 2 February 2008
2 Actinic keratosis (AK) is an important precursor lesion for cutaneous SCC, and is the first visible manifestation of SCC in the skin. 2 Some experts have suggested that AK is actually an early cancer, 2 although it is more typically described as an early precancerous lesion. AKs develop in skin that is photodamaged, and they may eventually progress to SCC in situ and then subsequently to invasive SCC. AK is a very common skin condition, with an estimated prevalence rate of 11% to 25% of adults in North America. According to the American Academy of Dermatology, approximately 60% of adults in the United States who have high-risk features (eg, fair skin) will develop at least 1 AK during the course of a lifetime. 5 Important risk factors for AK include advanced age, fair skin, and chronic sun exposure. 6 AK is more common among men than women, perhaps as a consequence of greater sun exposure. Other risk factors include exposure to carcinogens (eg, arsenic and coal tar), certain congenital conditions that predispose to skin cancer, and conditions that cause suppression of the immune system. Immunosuppressive regimens to reduce the risk of tissue rejection following organ transplantation are associated with a very high risk of AK and invasive skin cancers. 6,7 Cutaneous SCC is a significant cause of death following organ transplantation, and is the leading cause of death among these patients in some countries. 8,9 Although the pathogenesis of AK is not completely understood, DNA damage caused by chronic exposure to sunlight (especially to ultraviolet [UV]-B radiation) is thought to be central to the development of AK. 10 DNA repair mechanisms normally counteract DNA damage that is caused by UV radiation. However, the accumulation of several DNA mutations may overcome these repair mechanisms. Mutations to the P53 gene, which normally acts to suppress many types of cancer, may be especially important in the pathogenesis of AK. Chronic UV exposure also increases AK by inducing immunosuppression. 11 The incubation time for AK is very long, with lesions often appearing 20 to 40 years after periods of extensive sun exposure. It should be noted that chronic low-intensity sun exposure is sufficient to induce the formation of AKs, and that episodes of sunburn are not necessary. Individual AK lesions may spontaneously remit, they may persist as AKs for a long period of time, or they may progress to SCC in situ or to invasive SCC. 6,10 The likelihood that a patient will progress from AK to invasive skin cancer is largely a function of the number of lesions and the amount of time that the lesions have been present. Estimates of the rate of progression of individual AK lesions have varied widely, from as low as 0.025% to as high as 16% per year. 12 It has been estimated that a typical patient with 8 AKs would have a 10% chance of progressing to invasive SCC over a 10-year period. 13 Factors that are associated with an increased risk of progression to invasive SCC are similar to risk factors for the initial development of AK, and include older age, male sex, the presence of multiple AKs, chronic immunosuppression, and the type of AK, with some large, hypertrophic AKs and AKs with aggressive histologic features (eg, proliferative AKs) being considered higher risk. CLINICAL AND HISTOPATHOLOGIC FEATURES Actinic keratoses typically appear as red scaly or flaky lesions, sometimes accompanied by crusting. They may also be skin colored, brown, or pink. Regardless of color, AKs typically have a rough, sandpaper-like texture, and they are often easier to feel than to see. 10,14 Lesions appear on sun-exposed portions of the skin, including the scalp, the face, the dorsal surfaces of the hands, the chest, and the forearms. They may vary considerably in size, from as small as 1 mm to as large as several centimeters in diameter. The typical appearance of AK lesions is shown in Figure Figure 1. Clinical Presentation of Actinic Keratosis Reprinted with permission from Dragieva et al. Transplantation. 2004;77: Johns Hopkins Advanced Studies in Medicine 31
3 Although several AKs are clearly visible in this figure, it is likely that palpation would identify additional lesions by the presence of a rough, gritty skin surface. There are several different clinical variants of AK, several of which are shown in Figure 2. 7,14 Actinic cheilitis is a manifestation of AK that involves the lip (typically the lower lip, which receives greater sun exposure). Actinic keratosis is usually diagnosed clinically, on the basis of appearance and palpation of the lesion. 2 A shave or punch biopsy is a simple procedure that may be performed if there is concern that the lesion has progressed to SCC. A biopsy is not required for the routine diagnosis of AK. The most common reason for skin biopsy is to evaluate a lesion that has not responded to repeated attempts at treatment. Other reasons to perform a biopsy include large lesion size or a lesion that is much larger than surrounding lesions, ulceration, or bleeding. Actinic keratosis is defined histologically by the appearance of atypical keratinocytes within the deeper portion of the epidermis. Whereas SCC involves invasion of the dermis, AK is confined to the epidermis. 16 It may be reliably diagnosed by a dermatopathologist from tissue samples stained with hematoxylin and eosin stain. Characteristic features on histopathologic examination include atypical keratinocytes with loss of polarity, nuclear pleomorphism, disordered maturation, and increased numbers of mitotic features. Surrounding sun-damaged skin may exhibit solar elastosis of the dermis and superficial parakeratosis. 14,17 The differential diagnosis of AK includes warts, seborrheic keratosis, seborrheic dermatitis, SCC in situ (Bowen disease), and invasive SCC. 7 Seborrheic keratosis appears as gray, brown, or black lesions with a stuck-on appearance and dot-like stippling, usually appearing on the back or chest. Seborrheic dermatitis is a yellow, greasy, scale-like dandruff that affects the face and chest. AK may usually be distinguished from SCC by the size and thickness of the lesion (Figure 3), and by biopsy if necessary. Irritated or inflamed seborrheic keratosis and AK may be difficult to clinically differentiate. Figure 2. Clinical Variants of Actinic Keratosis Hyperkeratosis Pigmented Reprinted with permission from Berman et al. J Fam Pract. 2006;55: Figure 3. Squamous Cell Carcinoma In situ squamous cell carcinoma Confluent Cutaneous horn Invasive squamous cell carcinoma Reprinted with permission from 32 Vol. 8, No. 2 February 2008
4 ACTINIC KERATOSIS PREVENTION AND TREATMENT All patients should be encouraged to use simple preventive measures to reduce the risk of skin cancer. 18 Sunscreen with a skin protection factor of at least 30 should be applied to all sun-exposed portions of the skin 15 to 30 minutes before sun exposure. Sunscreen should be reapplied every 2 hours, after perspiring heavily, or after swimming. Patients should be reminded to use sunscreen even on cloudy days. Sun-protective clothing should include light-colored, tightly woven garments with long sleeves and pant legs, and a hat with a broad brim that shields the face, head, and neck. Exposure to UV radiation may be minimized by limiting outdoor activities during hours of maximum solar intensity (between 10 AM and 4 PM). Tanning salons should be avoided. Self-examination may be performed using a large mirror and a hand-held mirror. A regular self-examination for patients with a history of AKs (eg, once monthly) can help to identify skin changes for further evaluation by a physician. Regular examination by a physician is important for patients who are at high risk of developing AKs. As noted earlier in this article, AKs are associated with a substantial long-term risk of progression to SCC. These cancers are not only disfiguring, but may become metastatic, at which point they are essentially incurable. It is not possible to predict which AKs will eventually progress to SCC. For this reason, professional societies, such as the American Academy of Dermatology, the American Cancer Society, and the Skin Cancer Foundation, recommend treatment of all AK lesions to prevent the progression to invasive cancer. 19 In general, treatments for AK may be classified as either lesion-directed therapy (usually selected for patients with a small number of lesions) or fielddirected therapy (treatment of entire regions of skin containing several AKs in close proximity and surrounded by extensive photodamage). 14 Methods for lesion-directed therapy of AK include cryosurgery, surgical excision, and electrodessication and curettage. 5,14 Cryosurgery using liquid nitrogen is the most common method of treating isolated AKs, and is especially useful for lesions that are relatively small in diameter, thin, and well demarcated. Liquid nitrogen may be delivered using a cotton-tip applicator or a spray device. These techniques freeze the lesion, forming an ice ball that gradually separates and exfoliates over the next few days. Most lesions respond EVIDENCE-BASED PRACTICE RECOMMENDATIONS I. Practice Recommendation: For the treatment of AK, a principal goal in primary care is to minimize the risk of progression of AK to invasive SCC. Therefore, patient follow-up is important, particularly when treating AK, as lesions may recur or progress to SCC. 5-FU, imiquimod, and diclofenac are options for the topical therapy of AK. Name of AAFP-Approved Source: Guidelines for the Management of Actinic Keratoses. European Dermatology Forum. Specific Web Site of Supporting Evidence from Approved Source: Strength of Evidence: The European Dermatology Forum has recently issued updated management recommendations for AK. The guidelines noted that AK is an ongoing disease that requires regular follow-up and long-term management (consensus opinion; strength of evidence, C). The guidelines note that several topical agents have been shown to be effective for AK clearance, including imiquimod (2 randomized, double-blind, vehicle-controlled clinical trials with a total of 473 patients; strength of recommendation, A), 5-FU (consensus opinion, usual practice; strength of recommendation, C), and diclofenac (3 randomized, double-blind, placebo-controlled clinical trials with a total of 441 patients; strength of recommendation, A). II. Practice Recommendation: Photodynamic therapy is a process in which a photosensitizing agent is applied to the skin, and illumination of the exposed area with light of the appropriate wavelength transforms the photosensitizing agent to a cytotoxic intracellular product. Photodynamic therapy is effective for the treatment of AKs of the face and scalp. Name of AAFP-Approved Source: Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, J Am Acad Dermatol. 2007;56: Specific Web Site of Supporting Evidence from Approved Source: ?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pub med.pubmed_resultspanel.pubmed_rvdocsum. Strength of Evidence: Evidence-based treatment guidelines regarding the use of photodynamic therapy for nonmelanoma skin cancer were developed by the International Society for Photodynamic Therapy in Dermatology. The authors identified 6 randomized, double-blind, controlled clinical trials (with a total of 673 patients) demonstrating the efficacy of photodynamic therapy for the treatment of AK (strength of recommendation, A). Treatment response rates in these studies were approximately 90%. Johns Hopkins Advanced Studies in Medicine 33
5 completely to a single application of liquid nitrogen when treated with adequate freezing times (5 20 seconds). 20 If liquid nitrogen is not available, light electric cautery followed by curettage is sufficient in most cases. Surgical treatment is sometimes used for AK lesions, and also provides diagnostic information for a suspected SCC. Field-directed therapy is useful when it would be impractical to freeze all of the lesions individually. In addition, the presence of several lesions within an area of sun-damaged skin suggests the possibility of additional subclinical AKs. Field-directed therapy of the entire area treats both the visible lesions and these subclinical lesions, which might develop over the next several months without treatment. Several topical medications are available for field-directed therapy of AK. Topical 5-fluorouracil (5-FU) has been used for decades to treat AK, and remains widely used for this indication. Imiquimod is a topical immune modulator that locally stimulates antigen presenting cells, resulting in increased release of inflammatory cytokines at the application site. 21,22 Imiquimod may be less irritating than 5-FU, but may also produce a somewhat lower rate of complete AK removal. 14 Diclofenac, which is available in a topical gel, is a nonsteroidal anti-inflammatory drug that significantly reduces AK lesions, but is generally considered less efficacious than imiquimod or 5-FU. 6,23 All of these agents are typically applied for several weeks (typically, 8 12 weeks or even up to 16 weeks in some cases). The goal of treatment is to produce a vigorous inflammatory reaction, resulting in redness, crusting, and swelling. In clinical studies of field-directed therapy for AK, the magnitude of this response has been significantly associated with the eventual response to treatment. 14 This response must be maintained at an intensity that is just short of unbearable for the entire duration of treatment. The use of these agents in clinical practice is described in more detail in a patient case study presented later in this monograph by Neil Brooks, MD. Photodynamic therapy is another option that is effective for the treatment of widespread AKs. 24 The lesion is treated with a photosensitizing agent (5-aminolevulinic acid) that is taken up preferentially by dysplastic cells or altered cells. Upon exposure to an appropriate light source, the photosensitizing agent is converted to a cytotoxic chemical. Photodynamic therapy usually produces complete clearing of AKs with a single treatment session. Adverse effects include acute stinging or burning, which resolves within 24 hours, in addition to redness and scaling that may persist for approximately 1 week. 24 This approach is often useful for individuals who have employment or social responsibilities that require frequent public interaction or who otherwise prefer to avoid the chronic daily treatments required with the topical agents described previously. Destructive therapies, such as dermabrasion or chemical peels, are not used specifically for the treatment of AK, but may be used after treatment for cosmetic reasons. Laser resurfacing using a carbon dioxide laser has also been used for this purpose, although anecdotal reports have suggested that laser resurfacing may actually increase the risk of AKs in susceptible individuals (Jeffrey Dover, personal communication). CONCLUSIONS Actinic keratosis is a common condition that may progress to invasive SCC if not treated. It is not possible to predict with certainty which AKs will progress to SCC, thus treatment of all AK lesions is recommended by several professional societies. AKs are easily identified by appearance and palpation, and generally respond well to a range of treatment options. Nearly all of the deaths caused by invasive SCC in the United States are preventable by the early recognition and treatment of AKs. REFERENCES 1. McGovern TW, Leffell DJ. Actinic Keratoses and Non- Melanoma Skin Cancer. Available at: professionals/residents/medstudcorecurr/dcactinicker- NoMelCancer.htm. Accessed October 22, Lober BA, Lober CW. Actinic keratosis is squamous cell carcinoma. South Med J. 2000;93: Glass AG, Hoover RN. The emerging epidemic of melanoma and squamous cell skin cancer. JAMA. 1989;262: Christenson LJ, Borrowman TA, Vachon CM, et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA. 2005;294: Drake LA, Ceilley RI, Cornelison RL, et al. Guidelines of care for actinic keratoses. Committee on Guidelines of Care. J Am Acad Dermatol. 1995;32: Merk HF. Topical diclofenac in the treatment of actinic keratoses. Int J Dermatol. 2007;46: Barnaby JW, Styles AR, Cockerell CJ. Actinic keratoses. Differential diagnosis and treatment. Drugs Aging. 1997;11: Vol. 8, No. 2 February 2008
6 8. Moosa MR, Gralla J. Skin cancer in renal allograft recipients experience in different ethnic groups residing in the same geographical region. Clin Transplant. 2005;19: Barrett WL, First MR, Aron BS, Penn I. Clinical course of malignancies in renal transplant recipients. Cancer. 1993;72: Anwar J, Wrone DA, Kimyai-Asadi A, Alam M. The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol. 2004;22: Matsumura Y, Ananthaswamy HN. Toxic effects of ultraviolet radiation on the skin. Toxicol Appl Pharmacol. 2004;195: Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000;42: Dodson JM, DeSpain J, Hewett JE, Clark DP. Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch Dermatol. 1991;127: Berman B, Bienstock L, Kuritzky L, et al. Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel. J Fam Pract. 2006;55: Dragieva G, Hafner J, Dummer R, et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation. 2004;77: Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma ( actinic keratosis ). J Am Acad Dermatol. 2000;42: Stockfleth E, Kerl H, Guideline Subcommittee of the European Dermatology Forum. Guidelines for the management of actinic keratoses. Eur J Dermatol. 2006;16: American Academy of Dermatology. Prevention. Available at: Accessed October 22, Patients urged to seek treatment for actinic keratoses, recommends the American Academy of Dermatology, the American Cancer Society, and the Skin Cancer Foundation. Cutis. 1999;63: Thai KE, Fergin P, Freeman M, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol. 2004;43: Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004;50: Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol. 2006;126: Wolf JE Jr, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001;40: Piacquadio DJ, Chen DM, Farber HF, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol. 2004;140: Johns Hopkins Advanced Studies in Medicine 35
Field vs Lesional Therapies for AKs 3/2/2019, 9:00-12 AM
Dilemmas and Challenges in Skin Cancer Therapies and Management Field vs Lesional Therapies for AKs 3/2/2019, 9:00-12 AM Roger I. Ceilley, M.D. Clinical Professor of Dermatology The University of Iowa
More informationClinical characteristics
Skin Cancer Fernando Vega, MD Seattle Healing Arts Clinical characteristics Precancerous lesions Common skin cancers ACTINIC KERATOSIS Precancerous skin lesions Actinic keratoses Dysplastic melanocytic
More informationCutaneous Malignancies: A Primer COPYRIGHT. Marissa Heller, M.D.
Cutaneous Malignancies: A Primer Marissa Heller, M.D. Associate Director of Dermatologic Surgery Department of Dermatology Beth Israel Deaconess Medical Center December 10, 2016 Skin Cancer Non-melanoma
More informationKnow who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated
Lindy P. Fox, MD Assistant Professor Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco Applies to adults without history of malignancy or premalignant
More informationKnow who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated
Lindy P. Fox, MD Associate Professor Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco Applies to adults without history of malignancy or premalignant
More informationIT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY
IT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY Skin, Bones, and other Private Parts Symposium Dermatology Lectures by Debra Shelby, PhD, DNP, FNP-BC, FADNP, FAANP Debra Shelby,
More informationLiving Beyond Cancer Skin Cancer Detection and Prevention
Living Beyond Cancer Skin Cancer Detection and Prevention Cutaneous Skin Cancers Identification Diagnosis Treatment options Prevention What is the most common cancer in people? What is the most common
More informationScottish Medicines Consortium
Scottish Medicines Consortium imiquimod 5% cream (Aldara) No. (385/07) Meda Pharmaceuticals Ltd 04 April 2008 The Scottish Medicines Consortium has completed its assessment of the above product and advises
More informationSkin Cancer. Dr Elizabeth Ogden Associate Specialist in Dermatology East and North Herts Dr Elizabeth Ogden
Skin Cancer Dr Elizabeth Ogden Associate Specialist in Dermatology East and North Herts 13.10.16 Skin Cancer Melanoma mole cancer - is a true cancer which can metastasize and kill Non Melanoma skin cancer
More informationIdentifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018
Identifying Skin Cancer Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018 American Cancer Society web site Skin Cancer Melanoma Non-Melanoma
More informationTCA 35% for Actinic Keratoses. Emily C Keller MD, FAAD Annual AAD Meeting 2019
TCA 35% for Actinic Keratoses Emily C Keller MD, FAAD Annual AAD Meeting 2019 DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Emily C Keller, MD F116 Superficial, Medium, and Deep Chemical Peeling and Relevance
More informationLarge majority caused by sun exposure Often sun exposure before age 20 Persons who burn easily and tan poorly are at greatest risk.
Basics of Skin Cancer Detection and Treatment of Non- Melanoma Skin Cancers Large majority caused by sun exposure Often sun exposure before age 20 Persons who burn easily and tan poorly are at greatest
More informationActinic keratosis (AK): Dr Sarma s simple guide
Actinic keratosis (AK): Dr Sarma s simple guide Actinic keratosis is a very common lesion that you will see in your day-to-day practice. First, let me explain the name Actinic keratosis. It means keratosis
More informationI have a skin lump doc! What s next? 12 th August 2017 Dr. Sue-Ann Ho Ju Ee
I have a skin lump doc! What s next? 12 th August 2017 Dr. Sue-Ann Ho Ju Ee Some thoughts Is this skin cancer? How common is this? How likely is this in this patient? What happens next if it s something
More informationGeneral information about skin cancer
Skin Cancer General information about skin cancer Key points Skin cancer is a disease in which malignant (cancer) cells form in the tissues of the skin. There are different types of cancer that start in
More informationDermatology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI Memorial
Dermatology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI Memorial Cutaneous Oncology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI
More informationBenign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc
1 Benign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc Benign lesions Seborrheic Keratoses: Warty, stuck-on Genetics and birthdays Can start in late
More informationDiagnosis and Management of Actinic Keratosis (AKs)
Diagnosis and Management of Actinic Keratosis (AKs) Andrei Metelitsa, MD, FRCPC, FAAD Co-Director, Institute for Skin Advancement Clinical Associate Professor, Dermatology University of Calgary, Canada
More informationLearning Objectives. Tanning. The Skin. Classic Features. Sun Reactive Skin Type Classification. Skin Cancers: Preventing, Screening and Treating
Learning Objectives Skin Cancers: Preventing, Screening and Treating Robert A. Baldor, MD, FAAFP Professor, Family Medicine & Community Health University of Massachusetts Medical School Distinguish the
More informationSkin Cancer. 5 Warning Signs. American Osteopathic College of Occupational and Preventive Medicine OMED 2012, San Diego, Monday, October 8, 2012 C-1
Skin Cancer AMERICAN OSTEOPATHIC COLLEGE OF OCCUPATIONAL & PREVENTIVE MEDICINE OMED 2012 October 8, 2012 E. Robert Wanat II, D.O., M.P.H. Learning Objectives: Identify the 3 Basic Types of Skin Cancer
More informationMECHANISMS OF HUMAN DISEASE: LABORATORY SESSION PATHOLOGY OF THE SKIN LAB. Friday, February 12, :30 am 11:00 am
MECHANISMS OF HUMAN DISEASE: LABORATORY SESSION PATHOLOGY OF THE SKIN LAB Friday, February 12, 2012 9:30 am 11:00 am FACULTY COPY GOALS: Describe the basic clinical and morphologic features of various
More informationSkin Cancer - Non-Melanoma
Skin Cancer - Non-Melanoma Introduction Each year, millions of people find out that they have skin cancer. Skin cancer is almost 100% curable if found early and treated right away. It is possible to prevent
More informationPeriocular skin cancer
Periocular skin cancer Information for patients Skin cancer involving the skin of the eyelid or around the eye is called a periocular skin cancer. Eyelid skin cancers occur most often on the lower eyelid,
More informationDermatopathology: The tumor is composed of keratinocytes which show atypia, increase mitoses and abnormal mitoses.
Squamous cell carcinoma (SCC): A common malignant tumor of keratinocytes arising in the epidermis, usually from a precancerous condition: 1- UV induced actinic keratosis, usually of low grade malignancy.
More informationGlenn D. Goldman, MD. University of Vermont Medical Center. University of Vermont College of Medicine
Glenn D. Goldman, MD University of Vermont Medical Center University of Vermont College of Medicine Recognize and identify the main types of skin cancer and their precursors Identify and understand new
More informationMECHANISMS OF HUMAN DISEASE: LABORATORY SESSION PATHOLOGY OF THE SKIN LAB. Friday, February 13, :30 am 11:00 am
MECHANISMS OF HUMAN DISEASE: LABORATORY SESSION PATHOLOGY OF THE SKIN LAB Friday, February 13, 2009 9:30 am 11:00 am FACULTY COPY GOALS: Describe the basic clinical and morphologic features of various
More informationLimit Direct Sun Exposure
Summer is Too Hot. We love to be outdoors in the spring and the summer!!! We must take caution and protect our skin. May is Skin Cancer awareness month.. Skin Cancer Most avoidable of all cancers, skin
More informationHave a Voice in Your Choice!
Have a Voice in Your Choice! BLU-U Blue Light Photodynamic Therapy The LEVULAN KERASTICK for Topical Solution plus blue light illumination using the BLU-U Blue Light Photodynamic Therapy Illuminator is
More informationSQUAMOUS CELL CARCINOMA
SQUAMOUS CELL CARCINOMA What are the aims of this leaflet? This leaflet has been written to help you understand more about squamous cell carcinomas of the skin. It tells you what they are, what causes
More informationActinic Keratoses and Bowen s disease
Actinic Keratoses and Bowen s disease Delivering the best in care UHB is a no smoking Trust To see all of our current patient information leaflets please visit www.uhb.nhs.uk/patient-information-leaflets.htm
More informationSkin lesions The Good and the Bad. Dr Virginia Hubbard Ipswich Hospital NHS Trust Barts and the London School of Medicine and Dentistry
Skin lesions The Good and the Bad Dr Virginia Hubbard Ipswich Hospital NHS Trust Barts and the London School of Medicine and Dentistry Case 1 32 year old woman Australian Lesion on back New hair growing
More information1) Photodynamic therapy with topical 5 aminolevulinic acid is considered medically necessary and is covered for the treatment of:
Medical Policy Title: Photodynamic Therapy ARBenefits Approval: 10/26/2011 for Dermatologic Conditions Effective Date: 01/01/2012 Document: ARB0282:02 Revision Date: 03/20/2013 Code(s): 96567 Photodynamic
More informationPhotodynamic Therapy for the Treatment of Actinic Keratoses and Other Skin Lesions
Photodynamic Therapy for the Treatment of Actinic Keratoses and Other Skin Lesions Policy Number: Original Effective Date: MM.02.016 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST
More informationBL-5010P A NOVEL PRE-FILLED APPLICATOR FOR THE NON-SURGICAL REMOVAL OF SKIN LESIONS
BL-5010P A NOVEL PRE-FILLED APPLICATOR FOR THE NON-SURGICAL REMOVAL OF SKIN LESIONS 25 Skin lesions Miri Seiberg, PhD 26 Skin lesions A part of the skin that has an abnormal growth or appearance compared
More information30 Actinic Keratosis (Solar Keratosis)
30 Actinic Keratosis (Solar Keratosis) CLINICAL APPLICATION QUESTIONS A 65-year-old white man is seen at your office for multiple scaling lesions over his face, ears, neck, and the V of the chest. These
More informationCorporate Medical Policy
Corporate Medical Policy Dermatologic Applications of Photodynamic Therapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: dermatologic_applications_of_photodynamic_therapy 10/2003
More informationA Retrospective Study of Treatment of Squamous Cell Carcinoma In situ. Övermark, Meri.
https://helda.helsinki.fi A Retrospective Study of Treatment of Squamous Cell Carcinoma In situ Övermark, Meri 2016 Övermark, M, Koskenmies, S & Pitkanen, S 2016, ' A Retrospective Study of Treatment of
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 26 November 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 26 November 2008 ALDARA 5%, cream Box of 12 sachets of 250 mg (CIP: 349 204-4) Applicant: MEDA PHARMA imiquimod ATC
More informationSkin Cancer 101: Diagnosis and Management of the Most Common Cancer
Skin Cancer 101: Diagnosis and Management of the Most Common Cancer Sarah Patton, PA-C, MSHS Skin Surgery Center www.skinsurgerycenter.com Seattle/Bellevue, WA Skin cancer Skin cancer is by far the most
More informationPeriocular Malignancies
Periocular Malignancies Andrew Gurwood, O.D., F.A.A.O., Dipl. Marc Myers, O.D., F.A.A.O. Drs. Myers and Gurwood have no financial interests to disclose. Course Description Discussion of the most common
More informationTopical Diclofenac Gel, Fluorouracil Cream, Imiquimod Cream, and Ingenol Gel Prior Authorization with Quantity Limit Program Summary
Topical Diclofenac Gel, Fluorouracil Cream, Imiquimod Cream, and Ingenol Gel Prior Authorization with Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1-8 Topical Diclofenac Gel Indication
More informationDisclosures. I have no conflicts of interest to disclose
Disclosures I have no conflicts of interest to disclose Lindy P. Fox, MD Associate Professor Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco 2
More informationHealthy Skin Education in Alabama s Schools. Alabama Comprehensive Cancer Control Program
Healthy Skin Education in Alabama s Schools Alabama Comprehensive Cancer Control Program Skin cancer is the most common form of cancer in the US. Skin cancer is the uncontrolled growth of abnormal skin
More informationClinical Policy: Benign Skin Lesion Removal Reference Number: CP.MP.HN150
Clinical Policy: Reference Number: CP.MP.HN150 Effective Date: 6/04 Last Review Date: 8/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationSKIN CANCER. Most common cancer diagnosis 40% of all cancers
SKIN CANCER Most common cancer diagnosis 40% of all cancers OBJECTIVES Review common and uncommon cancers of the skin. Special emphasis on melanoma and dysplastic nevus Review pathology/tnm/staging, which
More informationWork Place Carcinogens Solar Radiation and Skin Cancer. November 2013 Dr Mark Foley
Work Place Carcinogens Solar Radiation and Skin Cancer November 2013 Dr Mark Foley Overview Work place carcinogens and skin cancer Who is a risk? Screening and Self skin exam Common skin cancers Many work
More informationA dinical and histopathologic entity associated with an increased risk of nonmelanoma skin cancer
PUVA keratosis A dinical and histopathologic entity associated with an increased risk of nonmelanoma skin cancer M. C. G. van Praag, MD, a J. N. Bouwes Bavinck, MD, a W. Bergman, MD, PhD, a F. R. Rosendaal,
More informationSkin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012
Skin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012 Case Presentation 57 yo man with 3 month hx of a nonhealing < 1 cm right
More informationSkin Cancer in Organ Transplant Recipients Challenges and Opportunities
Disclosure Skin Cancer in Organ Transplant Recipients Challenges and Opportunities Investigator: DUSA Pharmaceuticals, Inc. Investigator: Genentech Consultant: Gerson Lehrman Group Sarah Tuttleton Arron,
More informationInteresting Case Series. Aggressive Tumor of the Midface
Interesting Case Series Aggressive Tumor of the Midface Adrian Frunza, MD, Dragos Slavescu, MD, and Ioan Lascar, MD, PhD Bucharest Emergency Clinical Hospital, Bucharest University School of Medicine,
More informationGlenn D. Goldman, MD. Fletcher Allen Health Care. University of Vermont College of Medicine
Glenn D. Goldman, MD Fletcher Allen Health Care University of Vermont College of Medicine Recognize and identify the main types of skin cancer Understand how and why Mohs surgery is utilized for the treatment
More informationfluorouracil 0.5% / salicylic acid 10% cutaneous solution (Actikerall ) SMC No. (728/11) Almirall S.A.
fluorouracil 0.5% / salicylic acid 10% cutaneous solution (Actikerall ) SMC No. (728/11) Almirall S.A. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationBasal cell carcinoma 5/28/2011
Goal of this Presentation A practical approach to the diagnosis of cutaneous carcinomas and their mimics Thaddeus Mully, MD University of California San Francisco To review common non-melanoma skin cancers
More informationBenign and malignant epithelial lesions: Seborrheic keratosis: A common benign pigmented epidermal tumor occur in middle-aged or older persons more
Benign and malignant epithelial lesions: Seborrheic keratosis: A common benign pigmented epidermal tumor occur in middle-aged or older persons more common on the trunk; but extremities, head and neck are
More informationSkin Cancer Awareness
Skin Cancer Awareness Presented by BHS Call: 800-327-2251 Visit: www.bhsonline.com 2016 BHS. All rights reserved. 1 Training Summary More than 3.5 million new cases of skin cancer will be diagnosed in
More informationTalking to Your Clients About Skin Cancer. Objectives 9/9/2017. Amanda Friedrichs, MD, FAAD AMTA National Conference September 14, 2017
Talking to Your Clients About Skin Cancer Amanda Friedrichs, MD, FAAD AMTA National Conference September 14, 2017 Objectives Provide general information about skin cancer and how skin cancers commonly
More informationSteven Robinson. Steven Robinson Memorial Endowment at
fchwmt.org Steven Robinson Steven Robinson Memorial Endowment at Fair hair and skin Steven s story Grew up around water and loved being outdoors Experienced several sunburns as a child and young adult
More informationDisclosures. Melanoma and Non melanoma Skin Cancer: What You Need to Know. I have no conflicts of interest to disclose
Disclosures Melanoma and Non melanoma Skin Cancer: What You Need to Know I have no conflicts of interest to disclose Lindy P. Fox, MD Associate Professor Director, Hospital Consultation Service Department
More informationPatient Guide. The precise answer for tackling skin cancer. Brachytherapy: Because life is for living
Patient Guide Brachytherapy: The precise answer for tackling skin cancer Because life is for living Overview of skin cancer Skin cancer is the most common cancer worldwide. In fact more people are diagnosed
More informationThe future of Skin Cancer Treatment
The future of Skin Cancer Treatment What is ZaicaDerm? Fully formulated cream that delivers Tea Tree Oil in a transdermal format Using proprietary technology, ZaicaDerm, delivers 10% Tea Tree Oil below
More informationLUMPS AND BUMPS: AN ORGANIZED APPROACH TO DIAGNOSIS AND MANAGEMENT
LUMPS AND BUMPS: AN ORGANIZED APPROACH TO DIAGNOSIS AND MANAGEMENT Tammy P. Than, M.S., O.D., F.A.A.O. The University of Alabama at Birmingham / School of Optometry 1716 University Blvd. Birmingham, AL
More informationIngenol Mebutate: An Emerging Therapy in the Treatment of Actinic Keratoses
Curr Derm Rep (2013) 2:113 117 DOI 10.1007/s13671-013-0046-x MEDICAL SURGERY (CJ MILLER, SECTION EDITOR) Ingenol Mebutate: An Emerging Therapy in the Treatment of Actinic Keratoses Stephanie Jacks & Kasie
More informationIdentifying Benign and Malignant Skin Lesions. No Disclosures. Common Benign Lesions. Benign Lesions 2/25/2018. Stucco Keratoses.
Dermatology in Primary Care Identifying Benign and Malignant Skin Lesions Christy Quire Baker, APRN, FNP-BC, DCNP Dermatology Certified Nurse Practitioner No Disclosures Common Benign Lesions Seborrheic
More informationDermatological Manifestations in the Elderly. Sanjay Siddha Staff Dermatologist UHN & MSH
Dermatological Manifestations in the Elderly Sanjay Siddha Staff Dermatologist UHN & MSH Disclosure No actual or potential conflicts of interest or commercial relationships to declare Objectives Recognize
More informationOpinion 6 March 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 6 March 2013 EFFALA 8 mg, medicated plaster B/4 sachets (CIP code: 34009 397 996 4 3) B/8 sachets (CIP code: 34009
More informationEshini Perera 1,2, Sean McGuigan 2, Rodney Sinclair 2,3
RESEARCH ARTICLE Cost for the treatment of actinic keratosis on the rise in Australia [version 2; referees: 2 approved] Previously titled: Actinic keratosis on the rise in Australia Eshini Perera 1,2,
More informationSTUDY. Differences in Biopsy Techniques of Actinic Keratoses by Plastic Surgeons and Dermatologists. the most common reasons
STUDY Differences in Biopsy Techniques of Actinic Keratoses by Plastic Surgeons and Dermatologists A Histologically Controlled Pilot Study Klaus Sellheyer, MD; Wilma F. Bergfeld, MD Objective: To compare
More informationVACAVILLE DERMATOLOGY
Connecting the Dots on those Spots NANDAN V. KAMATH, M.D. VACAVILLE DERMATOLOGY Sources All of the photos were taken with permission from the Dermnet NZ website - Dermnet New Zealand after communicating
More informationNonmelanoma skin cancers
Skin cancer Philip Clarke Nonmelanoma skin cancers Treatment options Background Australia has one of the highest skin cancer rates in the world. Early detection and treatment of skin cancer is vital to
More informationPremalignant skin tumours
Chapter 14: Premalignant skin tumours page: 434 Premalignant skin tumours page: 435 Solar keratoses (senile keratoses) Raised red and well-defined plaques with a rough surface covered in scales of varying
More informationRichard Turner Consultant Dermatologist
Old Problems & New Treatments Photo Album by Administrator Richard Turner Consultant Dermatologist Plan for tonight? Refresher on SCC and solar keratosis How to distinguish the two Classic therapy than
More informationThe Sun and Your Skin
The Sun and Your Skin Karla S. Rosenman MD Park Nicollet Dermatology Skin Anatomy Skin Anatomy 1 Sunlight Ultraviolet (UV) radiation is carcinogenic to humans, causing all major types of skin cancer. UV-emitting
More informationDeveloping the next generation of dermatology products to treat serious skin diseases
Developing the next generation of dermatology products to treat serious skin diseases Tom Wiggans Chairman and Chief Executive Officer www.peplin.com Forward Looking Statements This presentation contains
More informationTOPICAL TREATMENT OF ACTINIC KERATOSIS
TOPICAL TREATMENT OF ACTINIC KERATOSIS Gary Goldenberg, MD Goldenberg Dermatology, PC Assistant Clinical Professor of Dermatology The Icahn School of Medicine at Mount Sinai Hospital Conflicts of Interest
More informationAlcohol should be avoided for 3 days prior to surgery and 2 days after the procedure.
Mohs Surgery Information Packet Be sure to bring the following to your appointment: Insurance Card Insurance Referral ( If required by your insurance) Name and address of your primary care provider as
More informationUNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE DOCTORAL THESIS SUMMARY
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE DOCTORAL THESIS SUMMARY CLINICAL, HISTOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL STUDY OF THE EPITHELIAL PRECANCEROUS LESIONS PRECURSORS OF
More informationDual Wavelength Phototherapy System
Dual Wavelength Phototherapy System The AKLARUS Blue and Red Combination System is an effective, drugfree alternative for treating acne & photodamaged skin. The non-invasive Aklarus treatment has been
More informationSkin & Allergy News. New Therapeutic Advances: Skin Cancer and Actinic Keratoses
A SUPPLEMENT TO Skin & Allergy News New Therapeutic Advances: Skin Cancer and Actinic Keratoses Update on Melanoma Common Nonmelanoma Skin Cancers: Basal Cell Carcinoma and Squamous Cell Carcinoma Actinic
More informationMedical Policy. MP Dermatologic Applications of Photodynamic Therapy
Medical Policy MP 2.01.44 BCBSA Ref. Policy: 2.01.44 Last Review: 12/27/2017 Effective Date: 12/27/2017 Section: Medicine Related Policies 2.01.47 Light Therapy for Psoriasis 8.01.06 Oncologic Applications
More informationMalignant Melanoma Early Stage. A guide for patients
This melanoma patient brochure is designed to help educate melanoma patients and their caregivers. It was developed under the guidance of Dr. Michael Smylie, Professor, Department of Oncology, University
More informationRegeneron and Sanofi are financial supporters of The Skin Cancer Foundation and collaborated in the development of this article. US-ONC /2018
A D E E P E R L O O K When detected early, most cases of local cutaneous squamous cell carcinoma are easily treated and usually cured. But when they become more advanced, this second most common form of
More informationA by-the-numbers assessment of therapies considers efficacy, convenience, cosmesis, and cost. By Amy Forman Taub, MD
A by-the-numbers assessment of therapies considers efficacy, convenience, cosmesis, and cost. By Amy Forman Taub, MD 8 Practical Dermatology February 007 Multiple treatment approaches exist for actinic
More informationExtreme dermatoheliosis: How to approach the severely sun damaged patient
Extreme dermatoheliosis: How to approach the severely sun damaged patient Anokhi Jambusaria MD, MSCE Staff Dermatologist Baylor Scott and White Health Round Rock, TX I have no relevant conflicts of interest
More informationMelanoma and Dermoscopy. Disclosure Statement: ABCDE's of melanoma. Co-President, Usatine Media
Melanoma and Dermoscopy Richard P. Usatine, MD, FAAFP Professor, Family and Community Medicine Professor, Dermatology and Cutaneous Surgery Medical Director, University Skin Clinic University of Texas
More informationIngenol Mebutate: A Succinct Review of a Succinct Therapy
Dermatol Ther (Heidelb) (2014) 4:157 164 DOI 10.1007/s13555-014-0061-2 REVIEW Ingenol Mebutate: A Succinct Review of a Succinct Therapy David Rhys Alchin To view enhanced content go to www.dermtherapy-open.com
More informationA PATIENT S GUIDE to MOHS MICROGRAPHIC SURGERY
A PATIENT S GUIDE to MOHS MICROGRAPHIC SURGERY Microscopically Controlled Surgery for Skin Cancer ALBUQUERQUE DERMATOLOGY ASSOCIATES, P.A. Sky B. Connolly, M.D. F.A.A.D A Checklist Before Surgery Please
More informationEXCESSIVE SUN EXPOSURE A DANGER FACTOR FOR THE SKIN
EXCESSIVE SUN EXPOSURE A DANGER FACTOR FOR THE SKIN When the weather warms up, we all like to get more sunshine. While better weather can make us feel brighter, we must also be aware of the dangers as
More informationMohs. Micrographic Surgery. For Treating Skin Cancer
Mohs Micrographic Surgery For Treating Skin Cancer Skin Cancer Basics Skin cancer is common. Over the past three decades, more people have had skin cancer than all other cancers combined. Each year in
More informationSquamous Cell Skin Cancer
Please complete our online survey at NCCN GUIDELINES FOR PATIENTS NCCN.org/patients/survey 2019 Squamous Cell Skin Cancer Presented with support from: Available online at NCCN.org/patients Ü Squamous Cell
More informationOBSERVATION. Decreased Skin Cancer After Cessation of Therapy With Transplant-Associated Immunosuppressants
OBSERVATION Decreased Skin Cancer After Cessation of Therapy With Transplant-Associated Immunosuppressants Clark C. Otley, MD; Brett M. Coldiron, MD; Thomas Stasko, MD; Glenn D. Goldman, MD Background:
More informationDon't Think Sun Tan, Think Skin Change
Don't Think Sun Tan, Think Skin Change Evaluation and treatment of actinic damage, basal and squamous cell cancer, solar lentigines & facial erythema Rebecca Small, M.D. Assistant Clinical Professor Preceptor,
More informationSUN, SAVVY AND SKIN : A REVIEW OF SKIN CANCER IN SOUTH AFRICA AND BEYOND
SUN, SAVVY AND SKIN : A REVIEW OF SKIN CANCER IN SOUTH AFRICA AND BEYOND Dr Lester M. Davids Redox Laboratory, Dept of Human Biology University of Cape Town Crafting a Road Map for Research on Sun Exposure
More informationSkin Cancer: Basal and Squamous Cell Overview
Skin Cancer: Basal and Squamous Cell Overview This overview is based on the more detailed information in our document Skin Cancer: Basal and Squamous Cell. You can get this document and other information
More informationSkin Care in Renal Transplant Patients
Skin Care in Renal Transplant Patients Introduction Skin Care in Renal Transplant Patients Skin care is very important for everyone, but particularly for renal patients who have received transplants. Because
More informationSkin Cancers Emerging Trends and Treatment Approaches
Skin Cancers Emerging Trends and Treatment Approaches Andrei Metelitsa, MD, FRCPC, FAAD Clinical Associate Professor, Dermatology, U of C Co-Director, Institute for Skin Advancement Copyright 2017 by Sea
More informationPathology of the skin. 2nd Department of Pathology, Semmelweis University
Pathology of the skin 2nd Department of Pathology, Semmelweis University Histology of the skin Epidermis: Stratum corneum Stratum granulosum Stratum spinosum Stratum basale Dermis: papillary and reticular
More informationSkin Cancer. There are many types of diseases. From a simple cold to the deadly disease
Skin Cancer Skin Cancer 1 There are many types of diseases. From a simple cold to the deadly disease Mesothelioma. Some diseases are almost harmless and some can kill you in less than a year. There are
More informationDermoscopy: Recognizing Top Five Common In- Office Diagnoses
Dermoscopy: Recognizing Top Five Common In- Office Diagnoses Vu A. Ngo, DO Department of Family Medicine and Dermatology Choctaw Nation Health Services Authority Learning Objectives Introduction to dermoscopy
More informationAWMSG SECRETARIAT ASSESSMENT REPORT. Ingenol mebutate (Picato ) 150 micrograms/g gel and 500 micrograms/g gel. Reference number: 1392 FULL SUBMISSION
AWMSG SECRETARIAT ASSESSMENT REPORT Ingenol mebutate (Picato ) 150 micrograms/g gel and 500 micrograms/g gel Reference number: 1392 FULL SUBMISSION This report has been prepared by the All Wales Therapeutics
More information